justbacked

Biotechnology, Clinical Trials, Oncology, Pharmaceutical

AdvanCell

AdvanCell raised $315M in a Series D announced on Jul 15, 2026, led by Eli Lilly, Alpha Wave Global, Catalio Capital Management, Bain Capital Life Sciences, SV Health Investors. Since then it has posted 14 roles (6 still open), the first on the day of the announcement. With 6 open roles it is hiring more than 6% of the 67 Series D+ startups on JustBacked (median: 48). In total it has raised $453M over 5 rounds from 22 investors.

Roles posted per month since the round
  • July 20263
  • September 202610
  • October 20261

From AdvanCell's own hiring system, by posting date. Tracked since Aug 21, 2026; roles that closed before then aren't counted.

AdvanCell develops targeted alpha radiopharmaceutical therapies for cancer and supports their development and manufacturing.

Why join AdvanCell?

Radiation that reaches only the tumor becomes the default cancer treatment, and older therapies start to look dated. AdvanCell, a Sydney radiopharmaceutical developer, is building that with targeted alpha therapies, and owning both development and manufacturing could make it a supplier drug makers rely on. Eli Lilly and Bain Capital Life Sciences sit among the leads on a $315M Series D, bringing its total to $453M across 5 rounds.

JustBacked's take, based on AdvanCell's own site and its funding and hiring data.

Series D · $315M · 129d agoadvancell.com.au

Hiring velocity

Open roles
6
Added, 30 days
+1
Added, 7 days
+0
Closed, 30 days
5
Raised
129 days ago
Led by
Eli Lilly, Alpha Wave Global, Catalio Capital Management, Bain Capital Life Sciences, SV Health Investors
Team size
51-100
HQ
Sydney, New South Wales, Australia
Newest role
25d ago
Tracked since
Aug 21, 2026

Where they're hiring

Science2
Operations1

Open roles at AdvanCell

Source: jobs.lever.co, checked daily.